110 related articles for article (PubMed ID: 9863218)
1. [Analysis of population pharmacokinetics with NONMEM in clinical patients treated with amikacin by intravenous infusion].
Chu XM; Rui JZ; Zhou YG; Dai YJ; Cai WM; Ling SS
Yao Xue Xue Bao; 1996; 31(12):881-5. PubMed ID: 9863218
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetic modeling and optimal sampling strategy for Bayesian estimation of amikacin exposure in critically ill septic patients.
Delattre IK; Musuamba FT; Nyberg J; Taccone FS; Laterre PF; Verbeeck RK; Jacobs F; Wallemacq PE
Ther Drug Monit; 2010 Dec; 32(6):749-56. PubMed ID: 20962708
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinectics of vancomycin and amikacin in the subeschar tissue fluid in patients with severe burn.
Yang RH; Rong XZ; Hua R; Zhang T
Burns; 2009 Feb; 35(1):75-9. PubMed ID: 18789586
[TBL] [Abstract][Full Text] [Related]
4. Serum cystatin C level for better assessment of glomerular filtration rate in cystic fibrosis patients treated by amikacin.
Halacova M; Kotaska K; Kukacka J; Vavrova V; Kuzelova M; Ticha J; Prusa R
J Clin Pharm Ther; 2008 Aug; 33(4):409-17. PubMed ID: 18613859
[TBL] [Abstract][Full Text] [Related]
5. [Pharmacokinetics of amikacin in the subeschar tissue fluid following severe burns].
Yang RH; Rong XZ; Zhang T; Hua R
Nan Fang Yi Ke Da Xue Xue Bao; 2007 Feb; 27(2):172-4. PubMed ID: 17355928
[TBL] [Abstract][Full Text] [Related]
6. [Assessment of pharmacokinetic parameters of amikacin in a group of neutropenic patients in onco-hematology].
Pivot-Dumarest C; Deweerdt C; Troncy J; Sorensen P; Roux D; Maire P
Pathol Biol (Paris); 1996 Apr; 44(4):299-305. PubMed ID: 8763595
[TBL] [Abstract][Full Text] [Related]
7. Increased amikacin dosage requirements in burn patients receiving a once-daily regimen.
Conil JM; Georges B; Breden A; Segonds C; Lavit M; Seguin T; Coley N; Samii K; Chabanon G; Houin G; Saivin S
Int J Antimicrob Agents; 2006 Sep; 28(3):226-30. PubMed ID: 16908121
[TBL] [Abstract][Full Text] [Related]
8. [Influence of total parenteral nutrition on amikacin pharmacokinetics].
Cai WM; Yu GH; Chen G
Zhongguo Yao Li Xue Bao; 1989 Sep; 10(5):428-31. PubMed ID: 2515746
[TBL] [Abstract][Full Text] [Related]
9. [Evaluation of population pharmacokinetics of cyclosporin A in renal transplantation patients with NONMEM].
Rui JZ; Zhuo HT; Jiang GH; Chen G
Yao Xue Xue Bao; 1995; 30(4):241-7. PubMed ID: 7660791
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetic analysis of amikacin and validation on neonates using Monte Carlo method.
Wang J; Liang WQ; Wu JJ; Pan CM
Acta Pharmacol Sin; 2000 Oct; 21(10):954-60. PubMed ID: 11501052
[TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in patients with complicated intra-abdominal infection.
Li C; Kuti JL; Nightingale CH; Mansfield DL; Dana A; Nicolau DP
J Antimicrob Chemother; 2005 Aug; 56(2):388-95. PubMed ID: 16002420
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetics of gentamicin in premature newborns.
García B; Barcia E; Pérez F; Molina IT
J Antimicrob Chemother; 2006 Aug; 58(2):372-9. PubMed ID: 16782742
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetic analysis of vancomycin in patients with gram-positive infections and the influence of infectious disease type.
Yamamoto M; Kuzuya T; Baba H; Yamada K; Nabeshima T
J Clin Pharm Ther; 2009 Aug; 34(4):473-83. PubMed ID: 19583681
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetics of four β-lactams in critically ill septic patients comedicated with amikacin.
Delattre IK; Musuamba FT; Jacqmin P; Taccone FS; Laterre PF; Verbeeck RK; Jacobs F; Wallemacq P
Clin Biochem; 2012 Jul; 45(10-11):780-6. PubMed ID: 22503878
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of population pharmacokinetic models for amikacin dosage individualization in critically ill patients.
Mar Fernández de Gatta MD; Victoria Calvo M; Ardanuy R; Domínguez-Gil A; Lanao JM; Moreno SR
J Pharm Pharmacol; 2009 Jun; 61(6):759-66. PubMed ID: 19505366
[TBL] [Abstract][Full Text] [Related]
16. Serum cystatin C for the prediction of glomerular filtration rate with regard to the dose adjustment of amikacin, gentamicin, tobramycin, and vancomycin.
Hermida J; Tutor JC
Ther Drug Monit; 2006 Jun; 28(3):326-31. PubMed ID: 16778715
[TBL] [Abstract][Full Text] [Related]
17. [Can we use a Bayesian method to build a pharmacokinetic population in two steps?].
Cabelguenne D; Bleyzac N; Pivot C; Maire P
Therapie; 2000; 55(2):277-82. PubMed ID: 10967700
[TBL] [Abstract][Full Text] [Related]
18. Disposition of single-dose intravenously administered amikacin in emus (Dromaius novaehollandiae).
Helmick KE; Boothe DM; Jensen JM
J Zoo Wildl Med; 1997 Mar; 28(1):49-54. PubMed ID: 9226616
[TBL] [Abstract][Full Text] [Related]
19. [Amikacin pharmacokinetics in adults: a variability that question the dose calculation based on weight].
Bourguignon L; Goutelle S; Gérard C; Guillermet A; Burdin de Saint Martin J; Maire P; Ducher M
Therapie; 2009; 64(1):47-53. PubMed ID: 19463252
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetics of a single daily intramuscular dose of gentamicin in children with severe malnutrition.
Seaton C; Ignas J; Muchohi S; Kokwaro G; Maitland K; Thomson AH
J Antimicrob Chemother; 2007 Apr; 59(4):681-9. PubMed ID: 17347177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
